REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
Fernando Muñoz 1
Cristina Rodriguez 2
Javier Pérez Gisbert 3
Isabel Vera Mendoza 4
Ana Gutiérrez-Casbas 5
Sabino Riestra 6
María Dolores Martín-Arranz 7
Pilar Martínez-Montiel 8
Vanesa Royo 9
Patricia Suárez 10
Esther García-Planella 11
Orlando Garcia-Bosch 12
Marisa Iborra 13
Jesus Aparicio 14
Ignacio Tagarro 14
Alonso Fernandez-Nistal 14
Carmen Montoto 14
Francisco Casellas 15
1 Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
2 Complejo Hospitalario de Navarra, Pamplona, Spain
3 Hospital Universitario de La Princesa, Madrid, Spain
4 Hospital Puerta de Hierro Majadahonda, Madrid, Spain
5 Hospital General Universitario de Alicante, Alicante, Spain
6 Hospital Universitario Central de Asturias, Oviedo, Spain
7 La Paz University Hospital, Madrid, Spain
8 Hospital Universitario 12 de Octubre, Madrid, Spain
9 Hospital Universitario Son Espases, Palma, Spain
10 Complejo Asistencial Universitario de León, León, Spain
11 Hospital de Sant Pau, Barcelona, Spain
12 Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain
13 La Fe University and Polytechnic Hospital, Valencia, Spain
14 Takeda Farmacéutica España S.A., Madrid, Spain
15 Hospital Universitari Vall d'Hebron, Barcelona, Spain
Session
IBD (Posters)
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]